Northern Trust Corp Supernus Pharmaceuticals, Inc. Transaction History

Northern Trust Corp

$572 Billion
Q1 2024

A detailed history of Northern Trust Corp transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 619,213 shares of SUPN stock, worth $16.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

619,213

Previous 648,446 4.51%

Holding current value

$16.8 Million

Previous $18.8 Million 12.55%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$27.11 - $35.17 $792,506 - $1.03 Million	-29,233 Reduced 4.51%	619,213 $21.1 Million
Q4 2023 Feb 13, 2024	SELL	$22.72 - $29.68 $1.95 Million - $2.54 Million	-85,704 Reduced 11.67%	648,446 $18.8 Million
Q3 2023 Nov 13, 2023	SELL	$27.57 - $32.91 $39,645 - $47,324	-1,438 Reduced 0.2%	734,150 $20.2 Million
Q2 2023 Aug 11, 2023	BUY	$29.91 - $38.73 $992,084 - $1.28 Million	33,169 Added 4.72%	735,588 $22.1 Million
Q1 2023 May 15, 2023	SELL	$34.93 - $42.03 $346,435 - $416,853	-9,918 Reduced 1.39%	702,419 $25.4 Million

Q4 2022 Feb 13, 2023	BUY	$31.09 - $37.88 $676,331 - $824,041	21,754 Added 3.15%	712,337 $25.4 Million
Q3 2022 Nov 14, 2022	SELL	$28.79 - $35.41 $21,534 - $26,486	-748 Reduced 0.11%	690,583 $23.4 Million
Q2 2022 Aug 12, 2022	BUY	$25.33 - $34.25 $1.58 Million - $2.14 Million	62,451 Added 9.93%	691,331 $20 Million
Q1 2022 May 13, 2022	SELL	$28.51 - $32.9 $711,552 - $821,118	-24,958 Reduced 3.82%	628,880 $20.3 Million
Q4 2021 Feb 08, 2022	SELL	$26.37 - $34.22 $124,308 - $161,313	-4,714 Reduced 0.72%	653,838 $19.1 Million
Q3 2021 Nov 15, 2021	SELL	$23.54 - $31.39 $369,483 - $492,697	-15,696 Reduced 2.33%	658,552 $17.6 Million
Q2 2021 Aug 13, 2021	BUY	$26.72 - $33.19 $2.25 Million - $2.8 Million	84,391 Added 14.31%	674,248 $20.8 Million
Q1 2021 May 12, 2021	SELL	$24.15 - $31.45 $601,552 - $783,388	-24,909 Reduced 4.05%	589,857 $15.4 Million
Q4 2020 Feb 11, 2021	SELL	$17.7 - $25.81 $580,878 - $847,032	-32,818 Reduced 5.07%	614,766 $15.5 Million
Q3 2020 Nov 16, 2020	SELL	$20.2 - $25.05 $525,381 - $651,525	-26,009 Reduced 3.86%	647,584 $13.5 Million
Q2 2020 Aug 14, 2020	SELL	$17.09 - $24.89 $269,475 - $392,465	-15,768 Reduced 2.29%	673,593 $16 Million
Q1 2020 May 14, 2020	BUY	$14.45 - $24.69 $280,243 - $478,837	19,394 Added 2.89%	689,361 $12.4 Million
Q4 2019 Feb 14, 2020	SELL	$19.93 - $29.13 $227,680 - $332,781	-11,424 Reduced 1.68%	669,967 $15.9 Million
Q3 2019 Nov 13, 2019	BUY	$25.47 - $33.37 $492,589 - $645,375	19,340 Added 2.92%	681,391 $18.7 Million
Q2 2019 Aug 13, 2019	BUY	$29.96 - $38.87 $154,443 - $200,374	5,155 Added 0.78%	662,051 $21.9 Million
Q1 2019 May 13, 2019	BUY	$32.77 - $41.99 $118,266 - $151,541	3,609 Added 0.55%	656,896 $23 Million
Q4 2018 Feb 12, 2019	SELL	$30.84 - $49.51 $184,515 - $296,218	-5,983 Reduced 0.91%	653,287 $21.7 Million
Q3 2018 Nov 14, 2018	BUY	$42.7 - $56.55 $968,137 - $1.28 Million	22,673 Added 3.56%	659,270 $33.2 Million
Q2 2018 Sep 18, 2018	SELL	$44.1 - $59.85 $144,251 - $195,769	-3,271 Reduced 0.51%	636,597 $38.1 Million
Q2 2018 Aug 14, 2018	BUY	$44.1 - $59.85 $1.12 Million - $1.52 Million	25,422 Added 4.14%	639,868 $38.3 Million
Q1 2018 May 09, 2018	SELL	$37.15 - $46.9 $1.12 Million - $1.42 Million	-30,216 Reduced 4.69%	614,446 $28.1 Million
Q4 2017 Feb 14, 2018	SELL	$36.4 - $42.6 $117,863 - $137,938	-3,238 Reduced 0.5%	644,662 $25.7 Million
Q3 2017 Nov 13, 2017	BUY	$36.75 - $49.65 $23.8 Million - $32.2 Million	647,900	647,900 $25.9 Million

Others Institutions Holding SUPN

# of Institutions

260

Shares Held

57.3M

Call Options Held

84.1K

Put Options Held

61.2K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.45B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Supernus Pharmaceuticals, Inc. Transaction History